image: Hyperpolarized [1-¹³C]mevalonolactone (MVL), a molecular probe for paraoxonase (PON) activity, was administered in vivo and monitored using hyperpolarized MRI. The technique enables highly sensitive, noninvasive visualization of PON activity in the liver and reveals a decrease in enzyme activity associated with the progression of metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH).
Credit: QST / Nippon Sanso Corporation
Chiba, Japan, November 12, 2026 ― Researchers in Japan have, for the first time, visualized the activity of an important liver enzyme in vivo using an MRI-based approach, potentially providing a new way to detect and monitor fatty liver disease. The condition can progress with few obvious warning signs and, in severe cases, can lead to liver inflammation, fibrosis, cirrhosis and liver cancer.
A joint research team led by Yoichi Takakusagi at the National Institutes for Quantum Science and Technology (QST), together with Daichi Kaneko and Akari Ikeda of Nippon Sanso Corporation and other collaborators, developed a molecular probe that enables the activity of an enzyme called paraoxonase (PON) to be visualized using hyperpolarized MRI. In mouse models of metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH), the researchers found that PON activity declined as the disease progressed. This study was published in Sensors & Diagnostics on November 12, 2026.
MASLD is a common condition in which excess fat builds up in the liver in association with metabolic disorders. It is estimated to affect about one in three adults. In some people, the disease progresses to MASH, liver fibrosis, cirrhosis and even liver cancer. PON, which is mainly produced in the liver, is involved in lipid metabolism and protecting against oxidative stress. Its activity has therefore attracted attention as a potential marker of metabolic changes in the liver. However, conventional blood tests cannot accurately reflect how the enzyme functions within the liver itself, where its activity is strongly influenced by the local biological environment.
To make that activity visible, the team designed a probe based on carbon-13-labelled mevalonolactone, or [1-¹³C]MVL. PON converts MVL into mevalonic acid (MVA). By detecting both molecules and comparing their signals, the researchers can visualize PON activity in the liver.
The researchers used a technique called hyperpolarization to temporarily boost the probe's MRI signal. Using a SpinAligner hyperpolarizer installed at QST's Institute for Quantum Life Science, the team achieved approximately 230,000-fold signal enhancement compared with conventional MRI conditions. The enhanced signal persisted long enough to detect both the probe and its metabolic product in vivo. In mice, a scan of about 20 seconds was sufficient to visualize PON activity in the liver.
The team then tested the approach in mice fed a special diet that induces MASLD and MASH. Compared with healthy control mice, the disease-model mice showed a progressive decline in liver PON activity as the disease progressed. These findings show that the probe can noninvasively detect disease-associated changes in enzyme activity in the living liver with high sensitivity.
“We wanted to find a way to see what enzymes are actually doing inside the living body, rather than relying only on blood tests,” said Yoichi Takakusagi, Group Leader at QST's Institute for Quantum Life Science. “The biggest challenge was developing a probe that produced a strong enough signal while still responding specifically to PON activity. Our new probe overcame that hurdle, allowing us to visualize changes in enzyme activity associated with the progression of fatty liver disease.”
The researchers say the implications could eventually extend beyond liver disease. By adapting the molecular-probe design to other enzymes, hyperpolarized MRI could open the way to a new class of imaging methods that visualize biochemical activity rather than anatomical changes alone. In the longer term, such techniques could contribute to earlier disease detection, assessment of disease progression, and more individualized treatment planning.
***
Reference
Title of original paper: A hyperpolarized 13C MRI molecular probe for in vivo imaging of paraoxonase activity
Journal: Sensors & Diagnostics
DOI: https://doi.org/10.1039/d6sd00164e
About National Institutes for Quantum Science and Technology, Japan
The National Institutes for Quantum Science and Technology (QST) was established in April 2016 to promote quantum science and technology in a comprehensive and integrated manner. The new organization was formed from the merger of the National Institute of Radiological Sciences (NIRS) with certain operations that were previously undertaken by the Japan Atomic Energy Agency (JAEA).
QST is committed to advancing quantum science and technology, creating world-leading research and development platforms, and exploring new fields, thereby achieving significant academic, social, and economic impacts.
About Dr. Yoichi Takakusagi
Dr. Yoichi Takakusagi is a Group Leader at the Institute for Quantum Life Science, National Institutes for Quantum Science and Technology (QST), Japan. His research focuses on hyperpolarized MRI/NMR, molecular imaging, and the development of diagnostic probes for precision medicine. He has contributed to the development of quantum-enabled imaging technologies for visualizing biological functions and metabolic processes in vivo.
Funding Information
Council for Science, Technology and Innovation (CSTI), Cross-ministerial Strategic Innovation Promotion Program (SIP)
Japan Science and Technology Agency (JST) FOREST JPMJFR225G
Ministry of Education, Culture, Sports, Science and Technology (MEXT) Q-LEAP JPMXS0120330644
MEXT Promotion of Development of a Joint Usage/Research System Project Coalition of Universities for Research Excellence Program (CURE) JPMXP1323015488
Journal
Sensors & Diagnostics
Method of Research
Experimental study
Subject of Research
Animals
Article Title
A hyperpolarized 13C MRI molecular probe for in vivo imaging of paraoxonase activity
Article Publication Date
12-Nov-2026
COI Statement
D. Kaneko, A. Ikeda, and J. Yokoyama belong to Nippon Sanso Co. Ltd. This study was conducted as a collaborative research project with Nippon Sanso Co. Ltd. Authors D. Kaneko, K. Saito, J. Yokoyama and Y. Takakusagi have filed a patent related to this work. The other authors declare no conflicts of interest.